Abivax (AAVXF) Total Current Liabilities (2021 - 2025)
Abivax has reported Total Current Liabilities over the past 5 years, most recently at $73.4 million for Q4 2025.
- Quarterly results put Total Current Liabilities at $73.4 million for Q4 2025, down 26.97% from a year ago — trailing twelve months through Dec 2025 was $73.4 million (down 26.97% YoY), and the annual figure for FY2025 was $71.2 million, down 30.02%.
- Total Current Liabilities for Q4 2025 was $73.4 million at Abivax, down from $100.4 million in the prior quarter.
- Over the last five years, Total Current Liabilities for AAVXF hit a ceiling of $100.4 million in Q4 2024 and a floor of $36.9 million in Q4 2021.
- Median Total Current Liabilities over the past 5 years was $73.4 million (2025), compared with a mean of $72.2 million.
- Biggest five-year swings in Total Current Liabilities: skyrocketed 85.85% in 2023 and later decreased 26.97% in 2025.
- Abivax's Total Current Liabilities stood at $36.9 million in 2021, then surged by 42.25% to $52.5 million in 2022, then surged by 85.85% to $97.6 million in 2023, then rose by 2.94% to $100.4 million in 2024, then decreased by 26.97% to $73.4 million in 2025.
- The last three reported values for Total Current Liabilities were $73.4 million (Q4 2025), $100.4 million (Q4 2024), and $97.6 million (Q4 2023) per Business Quant data.